Effects of lipo-prostaglandin E1 on pulmonary hemodynamics and clinical outcomes in patients with pulmonary arterial hypertension

Chest

Volumn 128, Issue 2, 2005, Pages 714-719

  Shen, Jieyan ^a,b   He, Ben ^a   Wang, Binyao ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Echocardiography; Exercise capacity; Lipo prostaglandin E1; Pulmonary arterial hypertension; Pulmonary hemodynamics

Indexed keywords

ANTICOAGULANT AGENT; CALCIUM ANTAGONIST; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LIPID; LIPOPROSTAGLANDIN E1; MICROSPHERE; NITRIC ACID DERIVATIVE; PREDNISONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COLLAGEN DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART OUTPUT; HUMAN; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG RESISTANCE; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; TREADMILL EXERCISE; VASCULAR DISEASE;

EID: 23744476410     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.128.2.714     Document Type: Article

References (18)

1. McLaughlin VV, Genthner DE, Panella MM, et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998; 338:273-277
2. Wax D, Garofano R, Barst RJ. Effects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension. Chest 1999; 116:914-920
3. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Am Intern Med 2000; 132:425-434
4. Yamaguchi T. Lipid microspheres as drug carriers: a pharmaceutical point of view. Adv Drug Deliv Rev 1996; 20:117-130
5. Mizushima Y, Hoshi K. Review: recent advances in lipid microsphere technology for targeting prostaglandin delivery. J Drug Target 1993; 1:93-100
6. Strange JW, Wharton J, Phillips PG, et al. Recent insights into the pathogenesis and therapeutics of pulmonary hypertension. Clin Sci 2002; 102:253-268
7. Murata I, Takenaka K, Yoshinoya S, et al. Clinical evaluation of pulmonary hypertension in systemic sclerosis and related disorders: a Doppler echocardiographic study of 135 Japanese patients. Chest 1997; 111:36-43
8. Shen JY, Chen SL, Wu YX, et al. Pulmonary hypertension in systemic lupus erythematosus. Rheumatol Int 1999; 18:147-153
9. Winslow TM, Ossipov MA, Fazio GP, et al. Five-year follow-up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus. Am Heart J 1995; 129:510-515
10. Mehta S. Drug therapy for pulmonary arterial hypertension: what's on the menu today? Chest 2003; 124:2045-2048
11. Sharma S. Treatment of pulmonary arterial hypertension: a step forward. Chest 2003; 124:8-10
12. Wanstall JC, Jeffery TK. Recognition and management of pulmonary hypertension. Drugs 1998; 56:989-1007
13. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind randomized controlled trial. Am J Respir Crit Care Med 2002; 165:800-804
14. Vizza CD, Sciomer S, Morelli S, et al. Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue. Heart 2001; 86:661-665
15. Machherndl S, Kneussl M, Baumgartner H, et al. Long-term treatment of pulmonary hypertension with aerosolized iloprost. Eur Respir J 2001; 17:8-13
16. 1 in pulmonary hypertension of collagen disease [case report]. Crit Care Med 1987; 15:884
17. 1 and epoprostenol (prostacyclin) in infants after heart surgery. Br Heart J 1991; 66:175
18. 1 in decompensated chronic obstructive pulmonary disease. Am Rev Respir Dis 1982; 125:1-5